EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model

Rawiwan Wongnak, Subbaian Brindha, Mami Oba iD, Takahiro Yoshizue, Md Din Islam iD, M Monirul Islam, Hitoshi Takemae iD, Tetsuya Mizutani, Yutaka Kuroda iD

Molecules · 2024

DOI: 10.3390/molecules29112676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Rawiwan Wongnak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-85…. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, Antibodies, Neutralizing, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Institute for Fostering Leadership to create future value through Outstanding Research, Innova-tion and Sustainable Higher education (FLOuRISH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Omicron BA.5 variant of SARS-CoV-2 is known for its high transmissibility and its capacity to evade immunity provided by vaccine protection against the (original) Wuhan strain. In our prior research, we successfully produced the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein in an E. coli expression system. Extensive biophysical characterization indicated that, even without glycosylation, the RBD maintained native-like conformational and biophysical properties. The current study explores the immunogenicity and neutralization capacity of the E. coli-expressed Omicron BA.5 RBD using a mouse model. Administration of three doses of the RBD without any adjuvant elicited high titer antisera of up to 7.3 × 105 and up to 1.6 × 106 after a booster shot. Immunization with RBD notably enhanced the population of CD44+CD62L+ T cells, indicating the generation of T cell memory. The in vitro assays demonstrated the antisera’s protective efficacy through significant inhibition of the interaction between SARS-CoV-2 and its human receptor, ACE2, and through potent neutralization of a pseudovirus. These findings underscore the potential of our E. coli-expressed RBD as a viable vaccine candidate against the Omicron variant of SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingCOVID-19Angiotensin-Converting Enzyme 2COVID-19 VaccinesAnimalsMiceHumansAntibodies, ViralDisease Models, AnimalProtein DomainsGlycosylationProtein BindingFemaleEscherichia coliT-Lymphocytes

Stichwörter der Autor:innen

E. coli-expression systemOmicron SARS-CoV-2disulfide bondsimmunogenicitylimited proteolysismolten globule statenative-like stateneutralizationnon-glycosylation

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, NeutralizingAngiotensin-Converting Enzyme 2COVID-19 VaccinesAntibodies, ViralACE2 protein, human

Autor:innen und Institutionen

  • Department of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.
  • Institute of Global Innovation Research, Tokyo University of Agriculture and Technology, Tokyo 183-8538, Japan.
  • Center for Infectious Disease Epidemiology and Prevention Research, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-Cho, Fuchu-shi 183-8509, Japan.
  • Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh.

ORCID-Profile: Mami Oba, Md Din Islam, Hitoshi Takemae, Yutaka Kuroda

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency
  • Institute for Fostering Leadership to create future value through Outstanding Research, Innova-tion and Sustainable Higher education (FLOuRISH)
  • JSPS Grant-in-Aid for Scientific Research
  • Institute of Global Innovation Research (GIR)
  • JST Program on Open Innovation Platform with Enterprises
  • Research Institutes and Academia (OPERA) Interdisciplinary Research Initiative
  • Integrated Photon Science, Institute for Fostering Leadership

Zitieren

APA

Wongnak, R., Brindha, S., Oba, M., Yoshizue, T., Islam, M. D., Islam, M. M., Takemae, H., Mizutani, T., & Kuroda, Y. (2024). Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model. Molecules. https://doi.org/10.3390/molecules29112676

Vancouver

Wongnak R, Brindha S, Oba M, Yoshizue T, Islam MD, Islam MM, et al. Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model. Molecules. 2024. doi:10.3390/molecules29112676

BibTeX
@article{Wongnak2024,
  author = {Wongnak, Rawiwan and Brindha, Subbaian and Oba, Mami and Yoshizue, Takahiro and Islam, Md Din and Islam, M Monirul and Takemae, Hitoshi and Mizutani, Tetsuya and Kuroda, Yutaka},
  title = {Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29112676}
}
Kostenlos starten →